• Natera and Eledon Pharmaceuticals announced a partnership to use the Prospera test in a global Phase 3 kidney transplant trial.
• Prospera will serve as the exclusive molecular monitoring assay for longitudinal surveillance in this large-scale study.
• The trial focuses on a novel immunosuppression therapy for kidney transplant recipients.

Natera, traded as NasdaqGS:NTRA, is extending its reach in transplant diagnostics with this new role for Prospera in a pivotal clinical trial. The company’s stock has seen a very large 3 year return and is up 55.9% over the past year, with a current share price of $261.91. Over shorter periods, the stock is up 13.2% over the past week and 28.9% over the past month, while the year to date return stands at 14.5%.

For investors following Natera, this development adds a fresh clinical research angle to the transplant story that the market may weigh alongside recent share price performance. How widely Prospera is used in future transplant trials and clinical settings will likely be a key factor to monitor as kidney transplant management practices continue to evolve.

Stay updated on the most important news stories for Natera by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Natera.

This partnership gives Natera another way to embed Prospera into real world transplant workflows. By becoming the exclusive molecular monitor in Eledon’s 600 patient Phase 3 trial of tegoprubart, Natera is tying its kidney transplant test to a late stage drug program that could influence how future immunosuppression regimens are designed and monitored. The large, global trial and regular Prospera testing may generate detailed molecular data on graft health under a novel anti CD40L antibody regimen, alongside standard clinical endpoints such as biopsy findings and graft function. For investors, the key angle is how this use of Prospera as trial infrastructure might translate into stronger physician familiarity and potential future use in routine kidney transplant care if tegoprubart progresses.

How This Fits Into The Natera Narrative

• The use of Prospera in a large Phase 3 transplant trial supports the narrative that Natera is building organ health as a second pillar next to oncology through broader clinical validation and closer ties to therapeutic decision making.
• At the same time, relying on outcomes from tegoprubart adds execution risk, since slower trial timelines or less compelling data could limit how much Prospera benefits from this specific program.
• The narrative emphasizes oncology and MRD testing, so the potential impact of large transplant therapy trials using Prospera as a monitoring backbone may not be fully reflected in investor expectations yet.

Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Natera to help decide what it's worth to you.

The Risks and Rewards Investors Should Consider

• ⚠️ Natera remains exposed to clinical and regulatory risk, since Prospera’s role in this trial does not guarantee future adoption if tegoprubart’s efficacy or safety profile is less compelling than expected or timelines slip.
• ⚠️ Heavy R&D and commercial spending across oncology and organ health can weigh on profitability if trial related exposure like this does not convert into scaled test ordering and favorable reimbursement.
• 🎁 If Prospera’s two threshold algorithm proves helpful for early detection of rejection or graft injury in this Phase 3 setting, it could strengthen Natera’s positioning against transplant monitoring tools from larger diagnostics groups such as Roche or Thermo Fisher.
• 🎁 Embedding Prospera into a global 600 patient study alongside Natera’s broader transplant collaborations may support the case that organ health testing can become a meaningful contributor alongside Signatera in oncology.

What To Watch Going Forward

From here, investors may want to track when Eledon’s Phase 3 trial actually starts enrollment, how many centers routinely use Prospera during the study, and what the design says about testing frequency and decision thresholds. Any future readouts that comment on Prospera’s ability to flag early graft injury relative to biopsies will be important for assessing its clinical value. It is also worth watching how this program sits alongside Natera’s other transplant efforts, including data presented at transplant meetings and agreements that link pre transplant risk scoring with Prospera monitoring, to see whether a more integrated transplant care model is taking shape over time.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Natera, head to the community page for Natera to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.